Sermorelin: what it is, how it's dosed, and how it compares to HGH

Last updated 2026-07-25

What is sermorelin, exactly?

Sermorelin is a synthetic peptide made of the first 29 amino acids of naturally occurring growth hormone-releasing hormone (GHRH), which is 44 amino acids long in its full form. That 29-amino-acid fragment turns out to carry all the biological activity needed to do the job: it binds to GHRH receptors on the pituitary gland and tells the gland to make and release growth hormone. This is the detail that gets lost in a lot of marketing copy. Sermorelin is not growth hormone. It's a signal that asks your pituitary to produce growth hormone on its own, using your body's normal pulsatile release pattern. That distinction drives almost every practical difference between sermorelin and injectable HGH, including how it's dosed, what side effects show up, and why some people simply won't respond to it. The compound has a real regulatory history, which is unusual for peptides sold today. It was approved by the FDA and marketed in the US under the brand name Geref, used mainly to diagnose and treat growth hormone deficiency in children. Geref was later discontinued by its manufacturer. That's a business decision about a small, aging product line, not a safety withdrawal, and it's worth being precise about that distinction because a lot of online chatter conflates "discontinued" with "pulled for danger." Since Geref's discontinuation, sermorelin has mostly been available through compounding pharmacies rather than as a manufacturer-produced, FDA-approved drug on pharmacy shelves. Sermorelin acetate is the specific salt form used in most compounded formulations, and it's the version you'll see referenced on lab certificates and prescription labels. When people search sermorelin peptide, sermorelin peptides, or peptide sermorelin, they're generally asking about this same compounded acetate form.

How does sermorelin work in the body?

Sermorelin works through the GHRH receptor pathway in the anterior pituitary. Once it binds there, it triggers a cascade that ends in the pituitary releasing growth hormone into the bloodstream in a pulse, similar to the body's natural overnight GH pulses. This matters because growth hormone secretion isn't a steady drip in a healthy person. It's episodic, with the biggest pulses happening during deep sleep. Sermorelin is designed to work with that rhythm rather than override it, which is the theoretical argument for why it might carry a gentler side effect profile than direct HGH injections. It doesn't flood the system with a fixed HGH dose regardless of what the body needs; it asks the pituitary to respond, and the pituitary still has some say in how much it releases. That also means sermorelin only works if the pituitary is still capable of producing growth hormone. If someone's pituitary is severely damaged or nonfunctional, sermorelin has nothing to stimulate. This is a core reason it's positioned differently from HGH for certain patient groups, and it's a question worth asking a prescriber directly before starting. One underappreciated wrinkle: GHRH signaling isn't limited to the pituitary in a simple, isolated way. A 1990 study in the Journal of Clinical Endocrinology and Metabolism looked at GHRH's effect on both maternal and fetal secretion of pituitary and placental growth hormone during pregnancy, showing that GHRH physiology operates across more than one tissue and one life stage ^[1]. That's not a treatment claim, it's a reminder that this axis is more layered than "peptide goes in, GH comes out."

What does sermorelin do for adults with low growth hormone?

In adults, sermorelin has been studied as a way to manage adult-onset growth hormone insufficiency by stimulating the person's own GH production instead of replacing it outright. A 2006 review in Clinical Interventions in Aging examined sermorelin specifically as an approach to this condition, framing it as an alternative strategy to direct GH replacement for adults whose pituitary still has some reserve capacity ^[2]. Separately, research in hypogonadal men has looked at growth hormone secretagogues, a category that includes sermorelin-like compounds, and their effect on body composition. A 2020 paper in Translational Andrology and Urology discussed the role of growth hormone secretagogues in managing body composition in hypogonadal males, positioning them as a tool that works alongside, not instead of, androgen-focused treatment ^[3]. A related 2017 study in the American Journal of Men's Health found that growth hormone secretagogue treatment in hypogonadal men raised serum IGF-1 levels ^[4], which is the standard downstream marker doctors use to confirm that GH stimulation is actually happening at the tissue level. None of this is a claim that sermorelin reverses aging, builds muscle on its own, or improves athletic performance. The honest read of the literature is narrower: in appropriate patients with some pituitary reserve, sermorelin can raise IGF-1 and support the GH axis. Whether that translates into a benefit you'd notice day to day depends heavily on why your GH is low in the first place, and that's a conversation for a prescriber working from your labs, not a peptide vendor's product page.

Sermorelin vs HGH: which one is actually right for you?

This is the question most people land on this page to answer, so here's the direct version: sermorelin and HGH are not interchangeable, and picking the wrong one for your situation wastes money and time. HGH (somatropin) is recombinant human growth hormone. It bypasses the pituitary completely and delivers GH directly. It's the standard of care for confirmed, severe growth hormone deficiency, particularly in children with diagnosed GH deficiency and in adults with panhypopituitarism or pituitary damage from tumors, surgery, or radiation. If your pituitary can't produce GH at all, sermorelin literally cannot help you, because there's nothing left for it to stimulate. Sermorelin only works if your pituitary still has functioning GHRH receptors and some reserve capacity to respond. In that scenario, it has a theoretical safety edge: because the pituitary retains control over how much GH it releases, sermorelin is less likely to cause the harder-edged HGH side effects like joint swelling, carpal tunnel symptoms, or excess fluid retention that come from flooding the body with a fixed external dose. But it's also weaker and slower. Nobody should expect sermorelin to produce HGH-level increases in circulating growth hormone; the ceiling is set by what your own pituitary is capable of making. Here's the practical comparison:

How is sermorelin dosed?

Sermorelin is most commonly dosed as a nightly subcutaneous injection, timed before bed to work with the body's natural overnight GH pulse. Compounded formulations are typically reconstituted from a lyophilized powder into a liquid the patient injects with a small insulin-type syringe. A sermorelin nasal spray formulation also exists in some compounding pharmacy catalogs, though absorption through the nasal mucosa is a very different delivery mechanism from subcutaneous injection, and the dosing math and reliability of that route is not the same as injectable sermorelin. If you're offered a nasal spray version, ask your prescriber directly how the dose was calculated for that delivery method rather than assuming it maps one-to-one onto injectable dosing. Exact dosing depends on the compounding pharmacy's formulation, the concentration in the vial, and the prescriber's protocol, so there's no single universal number that applies to everyone. This is a case where the specific instructions on your prescription label matter more than any general figure you'll find online. For the mechanics of drawing up a dose, choosing a site, and what week-to-week changes to expect, see our guides on sermorelin how to inject, sermorelin injection sites, and sermorelin timeline what to expect. One dosing-adjacent research note worth knowing: chemists have experimented with PEGylating GHRH analogs (attaching polyethylene glycol chains) specifically to extend how long the peptide stays active in the body, since native GHRH fragments are broken down quickly. A 2003 review in Advanced Drug Delivery Reviews covered PEGylation strategies for GRF (growth hormone-releasing factor) analogs aimed at improving their pharmacokinetic profile ^[7]. That's a reminder that the sermorelin fragment, on its own, doesn't last long in circulation, which is part of why consistent nightly dosing (not occasional use) is how it's typically prescribed.

Is sermorelin legal, and is it FDA-approved right now?

Sermorelin was FDA-approved under the brand name Geref, but that product is discontinued and is not currently marketed. There is no FDA-approved, brand-name sermorelin drug product on the market today; you can confirm current approval status for any drug name yourself using the FDA's Drugs@FDA database ^[5]. What's legal today is prescription access through pharmacy compounding, governed by 21 U.S.C. 353a, the federal statute that permits licensed pharmacists to compound drugs for individual patients under a valid prescription ^[6]. Compounding pharmacies work from lists of bulk drug substances the FDA has reviewed for use in compounding. Substances used by 503A pharmacies (traditional compounding pharmacies working from an individual prescription) are governed by the list in 21 CFR 216.23 ^[8], while 503B outsourcing facilities (which can compound in larger batches, including without a patient-specific prescription in some cases) work from the separate list at 21 CFR 216.24 ^[9]. The FDA also maintains a running list of bulk substances nominated for compounding consideration, which is a useful page to check for the current regulatory status of any peptide you're considering ^[10]. The practical takeaway: legitimate sermorelin access runs through a prescriber and a compounding pharmacy, not a research-chemical website. Peptides sold labeled "not for human consumption" or marketed for research use only are operating outside this framework, and their manufacturing isn't verified the same way a licensed pharmacy's is. A 2016 study in Drug Testing and Analysis documented falsified biopharmaceutical injectables circulating in Europe, a useful reminder that the gray market for injectable peptides has a real, documented counterfeiting problem ^[11].

What are the real risks and side effects of sermorelin?

The most commonly reported side effect of sermorelin is injection site reaction: redness, itching, or mild swelling where the shot goes in. Beyond that, headache and flushing have been reported in some patients, generally described as mild and dose-related in the clinical literature on GHRH analogs. Because sermorelin works through the body's own regulatory feedback loop rather than delivering a fixed external GH dose, it's generally considered to carry a lower risk of the harder GH-excess side effects (joint swelling, carpal tunnel-type nerve compression, insulin resistance at high doses) compared to direct HGH use. That's a mechanistic argument more than a large head-to-head trial result, so treat it as a reasonable expectation rather than a guarantee. Long-term, uncontrolled GH excess is a real risk category worth taking seriously, even if it's more associated with unsupervised HGH or growth hormone secretagogue misuse than with properly dosed sermorelin. A 2026 case report in Frontiers in Surgery described anterior cervical osteophyte-related dysphagia (difficulty swallowing caused by bone spur growth in the neck) in a long-term growth hormone user, illustrating a rare but documented structural consequence of sustained GH excess ^[12]. That case involved growth hormone use, not sermorelin specifically, but it's a useful data point on what unsupervised, long-duration GH-axis stimulation can eventually do to bone and soft tissue. For a full breakdown of what medications and conditions can interact with sermorelin therapy, and for guidance specific to women considering GH-axis peptides, see sermorelin drug interactions and sermorelin in women.

Does sermorelin have uses beyond growth hormone deficiency?

Most of the clinical interest in sermorelin outside classic GH deficiency is early-stage and specific, not a general wellness claim. Two examples from recent literature illustrate the range and the limits. A 2021 paper in Annals of Translational Medicine explored sermorelin as a potentially effective drug for patients with recurrent glioma, a type of brain tumor ^[13]. This is investigational research into a completely different application from hormone replacement, and it says nothing about sermorelin's use for GH deficiency or body composition; it's cited here specifically because it's real and because conflating it with mainstream sermorelin marketing would be misleading. On the orthopedic side, a 2026 paper in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews looked at therapeutic peptides broadly, including GH-axis peptides, in orthopedic applications, discussing both the potential and the current evidence gaps ^[14]. A related 2026 review in Sports Medicine examined the safety and efficacy of approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance, a category where sermorelin and similar GHRH analogs get used off-label without strong supporting trial data ^[15]. The honest summary: sermorelin's best-established use case remains supporting the GH axis in people with documented insufficiency and workable pituitary function. Anything beyond that (recurrent glioma, sports injury recovery, general performance) is investigational, thin on human trial data, or both. Be skeptical of any source that presents these early findings as settled benefits.

Why do athletic organizations test for sermorelin, and can it be detected?

Because sermorelin and related GHRH analogs can push GH and IGF-1 levels up without directly injecting GH itself, anti-doping labs have invested real effort into detecting them, and that effort tells you something about how seriously these peptides are treated in competitive sport. Multiple recent analytical chemistry papers describe methods built specifically to catch GHRH analogs like sermorelin in urine, plasma, and blood. A 2021 review in Drug Testing and Analysis covered advances in detecting synthetic GHRH analogs generally ^[16]. Groups have published cationic exchange solid-phase extraction methods combined with triple quadrupole mass spectrometry for urine detection ^[17], antibody-free ultrafiltration assays capable of detecting GHRHs at low picogram-per-milliliter concentrations ^[18], and immunoaffinity purification methods paired with high-resolution mass spectrometry for both plasma ^[19] and urine ^[20] samples. A 2023 paper in Biomedical Chromatography specifically studied the enzymatic and serum stability and degradation profile of GHRP and GHRH-related peptides, relevant to understanding how quickly these compounds break down in the body and how that affects detection windows ^[21]. This matters for two reasons if you're weighing sermorelin. First, if you're a tested athlete at any level governed by anti-doping rules, sermorelin is not a loophole; the analytical chemistry to catch it exists and keeps improving, as documented in a 2026 review on GH-IGF1 axis peptides bridging clinical evidence and patient self-administration in the Frontiers in Endocrinology journal ^[22], and a separate 2026 critical review in the Journal of Sports Medicine and Physical Fitness on peptide and peptide-analog drugs in recreational and professional sport ^[23]. Second, the sheer volume of detection research shows that GHRH analogs are being used outside clinical, prescribed settings often enough to justify building entire assay pipelines around catching them. That's a signal about the gray market, not an endorsement of using sermorelin for performance.

How do you get sermorelin legitimately, and what should you expect it to cost?

The legitimate path starts with a prescriber who reviews your symptoms, orders baseline labs (typically IGF-1, and sometimes a GH stimulation test), and confirms that GH-axis stimulation, rather than direct replacement, fits your situation. From there, a prescription goes to a licensed compounding pharmacy, since there's currently no FDA-approved, brand-name sermorelin product on the market to fill at a standard retail pharmacy. Cost varies by compounding pharmacy, concentration, and region, and there's no single reliable national average figure to quote here; compounded pricing simply isn't standardized the way brand-name drug pricing is tracked. What is reliable: compounded sermorelin is generally cheaper per month than brand-name recombinant HGH, partly because HGH is a more complex biologic to manufacture and partly because sermorelin doses needed to stimulate the pituitary are smaller than the doses needed to directly replace GH. Sermorelin Co works with a provider-reviewed process that connects patients to a licensed prescriber and a fulfilling compounding pharmacy partner; the company itself doesn't compound or manufacture anything, and no legitimate sermorelin source should skip the prescription step. If a seller offers to ship you sermorelin without ever involving a prescriber or asking about your labs, that's a sign you're outside the regulated supply chain described in 21 U.S.C. 353a ^[6], not inside it.

What should you ask a prescriber before starting sermorelin?

Bring three questions into that first conversation, because the answers determine whether sermorelin is even the right tool. First: what does my IGF-1 level actually show, and does it support a GH insufficiency diagnosis? Sermorelin isn't something to start on a hunch about fatigue or body composition; it's a response to a documented, lab-supported finding. Second: does my pituitary have the reserve capacity to respond to a GHRH signal? This is the crux of the sermorelin-versus-HGH decision covered earlier, and it's not something you can assess from symptoms alone. Third: what's the realistic timeline for noticing any change, and what does monitoring look like? Sermorelin works gradually, through the body's own pulsatile release, not through an immediate dose-response spike the way direct HGH injection does. If a prescriber can't answer these three questions with specifics tied to your labs, that's worth treating as a red flag.

Frequently asked questions

What is sermorelin used for?

Sermorelin is used to stimulate the pituitary gland's own production of growth hormone, mainly in adults and children with documented growth hormone insufficiency who still have functioning pituitary tissue. It was originally FDA-approved as Geref for this purpose. It is not a general anti-aging or performance product, despite how it's sometimes marketed online.

Is sermorelin the same as HGH?

No. HGH is recombinant growth hormone given directly. Sermorelin is a GHRH analog that signals your own pituitary to make growth hormone. Sermorelin only works if your pituitary still has functioning capacity; HGH works regardless because it bypasses the pituitary entirely.

Is sermorelin FDA-approved?

Sermorelin was FDA-approved under the brand name Geref, but Geref was discontinued by its manufacturer and is not currently marketed. There is no FDA-approved sermorelin brand product on the market today; check current status anytime in the FDA's Drugs@FDA database. Legal access now runs through prescription compounding.

Was Geref pulled from the market for safety reasons?

No. Geref was discontinued, which is a business and manufacturing decision, not a safety withdrawal. The FDA's own approved-drug database (Drugs@FDA) distinguishes discontinued products from those pulled for safety, and Geref falls into the discontinued category.

How is sermorelin different from a sermorelin nasal spray?

Standard sermorelin is given as a nightly subcutaneous injection. A nasal spray version exists through some compounding pharmacies, but nasal absorption is a different delivery mechanism with different dosing math than injection. Ask your prescriber specifically how dosing was calculated if you're offered the spray form.

How often do you inject sermorelin?

Most protocols use a nightly subcutaneous injection, timed before bed to align with the body's natural overnight growth hormone pulse. Exact frequency and dose depend on your prescriber's protocol and the compounding pharmacy's formulation, since there's no single universal dose that fits everyone.

What are the side effects of sermorelin?

The most common side effect is injection site redness, itching, or mild swelling. Headache and flushing are reported less often. Because sermorelin relies on the body's own feedback control rather than a fixed external GH dose, it's generally thought to carry lower risk of GH-excess side effects than direct HGH, though this is a mechanistic argument, not a guarantee from large trials.

Can sermorelin help with weight loss or muscle gain?

There's no strong clinical evidence supporting sermorelin as a weight loss or muscle-building product for people without documented GH insufficiency. Research in hypogonadal men found growth hormone secretagogues raised IGF-1 levels, but that's a hormonal marker, not a proven body composition outcome, and it applies to a specific patient population, not the general public.

Does sermorelin show up on a drug test?

Standard workplace drug panels don't screen for sermorelin. Anti-doping labs, however, have built specific, sensitive methods (immunoaffinity purification, high-resolution mass spectrometry, ultrafiltration assays) to detect GHRH analogs like sermorelin in urine, plasma, and blood at very low concentrations, so it is detectable in that testing context.

Is it legal to buy sermorelin online?

It's legal to obtain sermorelin through a valid prescription filled by a licensed compounding pharmacy, under the framework set by 21 U.S.C. 353a. Buying sermorelin from a site that ships it without a prescription or lab review sits outside that legal framework and carries real quality and safety uncertainty.

What's the difference between sermorelin and MK-677?

Sermorelin is an injectable GHRH analog that stimulates the pituitary through GHRH receptors. MK-677 is an oral ghrelin-mimetic growth hormone secretagogue that works through a different receptor pathway and is not FDA-approved for any use. See our mk 677 vs sermorelin comparison for the full breakdown.

Who should not use sermorelin?

People with a nonfunctional or severely damaged pituitary won't respond to sermorelin, since it has nothing left to stimulate; HGH is the appropriate option there instead. Anyone with an active malignancy, uncontrolled diabetes, or who is pregnant or breastfeeding should discuss those specific risk factors directly with a prescriber before considering it.

How long does it take to feel effects from sermorelin?

Sermorelin works gradually through the body's own pulsatile GH release rather than producing an immediate spike. Clinical literature on GHRH analogs describes a slower onset compared to direct HGH injection. Ask your prescriber for a realistic timeline tied to your specific labs and protocol rather than relying on general claims.

Sources

1. The Journal of Clinical Endocrinology and Metabolism, 1990 (PMID 2143200): GHRH affects both maternal and fetal secretion of pituitary and placental growth hormone during pregnancy
2. Clinical Interventions in Aging, 2006 (PMID 18046908): Sermorelin was reviewed as an approach to managing adult-onset growth hormone insufficiency
3. Translational Andrology and Urology, 2020 (PMID 32257855): Growth hormone secretagogues have a role in managing body composition in hypogonadal males
4. American Journal of Men's Health, 2017 (PMID 28830317): Growth hormone secretagogue treatment in hypogonadal men raised serum IGF-1 levels
5. FDA, Drugs@FDA database: Sermorelin (Geref) is not currently an FDA-approved marketed drug product; users can check current approval status directly
6. 21 U.S.C. 353a, pharmacy compounding statute: Federal law permits licensed pharmacists to compound drugs for individual patients under a valid prescription
7. Advanced Drug Delivery Reviews, 2003 (PMID 14499707): PEGylation strategies have been studied to extend the pharmacokinetic activity of GHRH (GRF) analogs
8. 21 CFR 216.23, 503A Bulks List: Traditional compounding pharmacies (503A) work from a federally defined list of permitted bulk drug substances
9. 21 CFR 216.24, 503B Bulks List: 503B outsourcing facilities work from a separate federally defined bulk drug substances list
10. FDA, bulk drug substances nominated for use in compounding: The FDA maintains a running list of bulk substances nominated for compounding consideration
11. Drug Testing and Analysis, 2016 (PMID 26456392): Falsified biopharmaceutical injectables have been documented circulating in the European gray market
12. Frontiers in Surgery, 2026 (PMID 42465868): A case report described anterior cervical osteophyte-related dysphagia in a long-term growth hormone user
13. Annals of Translational Medicine, 2021 (PMID 33842627): Sermorelin has been explored as a potentially effective drug for patients with recurrent glioma
14. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews, 2026 (PMID 41490200): Therapeutic peptides, including GH-axis peptides, are being studied for orthopedic applications with noted evidence gaps
15. Sports Medicine, 2026 (PMID 41966639): A review examined safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance
16. Drug Testing and Analysis, 2021 (PMID 34665524): Analytical chemistry advances have improved detection of synthetic GHRH analogs
17. Analytical Biochemistry, 2023 (PMID 37806509): A cationic exchange SPE method combined with UHPLC-MS/MS was developed to detect GHRHs in urine
18. Journal of Pharmaceutical and Biomedical Analysis, 2022 (PMID 35298973): An antibody-free ultrafiltration assay can detect GHRHs in urine at low picogram-per-milliliter concentrations
19. Analytical and Bioanalytical Chemistry, 2016 (PMID 26879649): GHRHs can be qualitatively identified in human plasma using immunoaffinity purification and LC-HRMS/MS
20. Journal of Pharmaceutical and Biomedical Analysis, 2026 (PMID 41138283): GHRH and its analogs can be analyzed in urine using nano liquid chromatography with quadrupole/orbitrap mass spectrometry
21. Biomedical Chromatography, 2023 (PMID 37688464): Enzymatic and serum stability and degradation profiles have been studied for GHRP and GHRH-related peptides
22. Frontiers in Endocrinology, 2026 (PMID 42395176): Performance-enhancing peptides modulating the GH-IGF1 axis are used through patient self-administration outside clinical evidence bases
23. Journal of Sports Medicine and Physical Fitness, 2026 (PMID 41880199): A critical review examined peptide and peptide-analog drug use in recreational and professional sport and bodybuilding